A phase 2 trial evaluating the combination of tafasitamab with lenalidomide is currently ongoing (NCT02005289), and preliminary data of the phase 2 trial testing tafasitamab combined with ibrutinib or venetoclax in CLL patients refractory to BTK inhibitors reported promising results in terms of ORR (44). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.